



BIOCLINICAL RADIOPHARMACEUTICALS LABORATORY

UMR U1039



Inserm

HEALTH

Molecular imaging

Nuclear medicine

Radiopharmaceuticals

Theranostics

Artificial intelligence

KEY FIGURES:

25 permanent researchers,
lecturers6 engineers and
administrative staff8 PhD students and
postdoctoral researchers160 publications per year
(on average)4 patents over the last
5 years

OVERVIEW

The *Bioclinical Radiopharmaceuticals Laboratory (LRB)* brings together researchers, academic staff, and clinician-scientists who work directly or indirectly in the field of medical imaging. Their mission is to develop nuclear imaging to improve patient care in the fields of cardiology, oncology, neurology and metabolism..

The two main research axes are: development of new radiopharmaceutical drugs (RPDs) and clinical valorization of existing RPDs. The unit has all the expertise required to carry out the development of these drugs—from identifying the clinical issue to clinical trials.

RESEARCH TOPICS

- Development of markers for vulnerable atherosclerotic plaques and atherothrombosis.
- Development of a marker for Tau protein oligomers in Alzheimer's disease.
- Development of an inflammation marker for non-alcoholic fatty liver disease.
- Development of theranostic agents in oncology.
- AI and image processing.

